drugset / Trial / NCT06593145
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
NaSingle-groupOpen-labelTreatment
Summary
One arm, open label study to assess the clinical use of Investigational Medicinal Product FCTX-CL19-1 (scientific name: Tarcidomgen Kimleucel) containing autologous anti-CD19 CAR T cells with a preliminary determination of the safety of intravenous IMP administration in patients diagnosed with refractory and relapsed CD19 + B cell neoplasms.
Timeline
- Start
- 2023-05-24
- Primary completion
- 2025-06
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FCTX-CL19-1 | Cell therapy | 200000 cells/kg | Intravenous |
| Subject | FCTX-CL19-1 | Cell therapy | 2e+06 cells/kg | Intravenous |